期刊文献+

美托洛尔与硝苯地平治疗老年人无症状性心肌缺血的疗效对比 被引量:4

Comparison of the efficacy of metoprolol and nifedipine in the treatment of asymptomatic myocardial ischemia for the elderly
原文传递
导出
摘要 目的探讨美托洛尔与硝苯地平治疗老年人无症状性心肌缺血的临床应用价值。方法选择56例无症状性心肌缺血老年患者,随机数字表法分为美托洛尔组和硝苯地平组各28例。分析两组治疗期间并发症发生情况、治疗前后发作次数及发作时间。结果美托洛尔组与硝苯地平组患者治疗前发作次数分别为(19.6±3.2)次/周与(18.9±2.8)次/周,发作时间(5131±-352)s与(5130±348)s,差异均无统计学意义(均P〉0.05);治疗后发作次数分别为(4.6±2.1)次/周与(7.4±2.1)次/周,发作时间(900±140)s与(1440±240)s,差异均有统计学意义(均P〈0.05)。所有患者治疗期间均能耐受,无心肌梗死病例出现。结论美托洛尔与硝苯地平对于老年人无症状性心肌缺血的治疗较为安全,美托洛尔较硝苯地平治疗效果好。 Objective To explore the clinical value of application of metoprolol and nifedipine in the treat- ment of asymptomatic myocardial ischemia for the elderly. Methods 56 cases of elderly patients with silent myocardial ischemia were chosen. They were randomly divideded into the metoprolol group of 28 cases and nifedipine group with 28 cases according to the number table. The incidence of complications during treatment in the metoprolol and nifedipine group were analyzed. The seizure frequency and onset time in the two groups of patients were compared before and after treatment. Results The onset time in the two groups, before treatment had no statistically significant difference [ the number of attacks : ( 19.6 ± 3.2 ) times/week compared with ( 18.9 ± 2.8 ) times/week; attack time : ( 5131 ± 352 ) s vs ( 5130 ± 348 ) s, all ( P 〉 0.05 ). After treatment, there were statistically significant differences for the number of attacks and attack time [ the number of attacks : (4.6 ± 2.1 ) times/week compared with ( 7.4 ± 2.1 ) times/week, onset time : ( 900 ± 140 ) s vs ( 1440 ± 240 ) s ( all P 〈 0.05 ). All patients can tolerate the treatment period,there was no cases of myocardial infarction occurs. Conclusion The metoprolol and nifedipine for the elderly treatment of silent myocardial ischemia was more secure, and metoprolol was more effective than nifedipine.
出处 《中国基层医药》 CAS 2012年第8期1143-1144,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 美托洛尔 硝苯地平治 无症状性心肌缺血 Metoprolol Nifedipine treatment Silent myocardial ischemia
  • 相关文献

参考文献15

  • 1Newry C. Adenosine and the concept of fetaliatory metabolites. Trends Biechem Sci,2007,9( 1 ) :42-44.
  • 2Lskandrlan S. New diretions in pharmacologic stress imaging. J Nucl Med,2005,36(2) :267.
  • 3侯广春,郭传智.卡维地洛与美托洛尔治疗慢性心力衰竭疗效比较[J].中国基层医药,2011,18(8):1043-1045. 被引量:28
  • 4张斌.卡维地洛对慢性心力衰竭患者心功能及血浆脑钠素水平的影响[J].中国基层医药,2010,17(3):403-404. 被引量:12
  • 5Cerqueira MD,Veranim S,Schwaiger M, et al. Safety profile of adenosine stress perfusion imaging:results from die Adenoscan Muhicenter Trim Registry. J Am Coil Cardiol,2004,23(2) :384-389.
  • 6Veranim S, Makmarian J, Mhlxson B, et al. Diagnosis of coronary artery disease by controlled coronary vasculation with adenosine and thallium-201 scintifraphy in patients unable to exercise. Circulation,2000,82 ( 1 ) :80.
  • 7Skandfian S. Myocardial ischemia during pharmacological stres stesting. Circulation ,2003,87 ( 3 ) : 1415-1417.
  • 8Lette J,Tatumj L,Fraser S,et al. Safe of dipyridamole testing in 73,806 patients:the Multieenter Dipyridamole Safe Study. J Nucl Cardiol,2005,2( 1 ) :3-17.
  • 9Devereuxb B,Alonsod B, Lutase M, et al. Echec ardiographic assessment of left ventricular hypertrophy : comparisonto necropsyfindings. Am J Cardio,2006,57(6) :450-458.
  • 10Mancia G, Seravlie G, Grassi G. Sympathetic nervous factors. pressure variability and organ damain arterial hypertension. Ann Ital Med Int,1997,12(4) :217-222.

二级参考文献38

  • 1帅锋利,李义勇,陈良海,郑小红.卡维地洛对慢性心力衰竭患者血清IL-6、TNF-α及运动耐量的影响[J].泸州医学院学报,2006,29(2):133-134. 被引量:1
  • 2梅霞,郑向清,田颖,李振魁,罗羽慧,王江,祝善俊.福辛普利和美托洛尔对心力衰竭患者血浆细胞因子及心脏功能的影响[J].心脏杂志,2006,18(6):650-652. 被引量:7
  • 3廖业敏,李宗开,程贞华,何君.卡维地洛对慢性心力衰竭患者心肌重构和炎性细胞因子的影响[J].中国心血管病研究,2007,5(7):530-532. 被引量:5
  • 4Ferro D, Parrotto, Basili S, et al. Simvastatin inhibits the monocyteex Pression of Proin flammatory cytokines, in Patients with hypercholes- terolemia. Coil Cardiol,2000,36 (2) :427-432.
  • 5Dao Q, Krishnaswamy P, Kazanergra R, et al. Utility of B-type natri-urtic peptide in diagnosis of congestive heart failure in an urgent care setting. J Am Coll Cardiol,2001,37 (2) ;379 - 385.
  • 6Maisel AM, Kreshnaswamy P, Nowak R, et al. B-type natriuretic peptide levels: Diagnostic and prognostic in congestive heart failure : What is next? Circulation ,2002,105 (16) :2328-2331.
  • 7Mukoyama A, Nakao K, Hosoda K ,et al. Brain natriuretic as a novel cardiac hormone in humans: Evidence for an exquisite kual natriure tic peptide system, atrial natriuretic peptide and brain natriurtic peptide. J Clin Invest, 1991,87 ( 5 ) : 1402 -1412.
  • 8Tsutamoto T, Wata A, Maeda K, et al. Plasma brain natriuretic peptide levels as a biochemical marker of morbidity and mortality in patients with asymptomatic of minimally symptomatic Deft ventri-cular dysfunction. Comparison with plasma angiotensin Ⅱ and endothelinl. Eue Heart J. 1999:20 (24):1402-1412.
  • 9Herman RB ,Jesudason PJ, Mustafa AM, et al. Difemtial efects of earvedilol and atenolol on plasma noradmaline during exercisein humans. Br J Clin Pharmacol,2003,55 ( 2 ) : 134-138.
  • 10Leehat P,Packer M,Chalon S,et al. Clinical elects of beta adrnergic blockade in chrnic heart failure: a meta analysis of doubleblind, placebo-contrlled , randomized trials. Circula-tion, 1998,98 (12) :1184-1191.

共引文献45

同被引文献23

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部